Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients
Authors:
- Emma J. WestEWEmma J. West
- Karen J. ScottKSKaren J. Scott
- Emma TidswellETEmma Tidswell
- Kaidre BendjamaKBKaidre Bendjama
- Nicolas StojkowitzNSNicolas Stojkowitz
- Monika LuskyMLMonika Lusky
- Marta KurzawaMKMarta Kurzawa
- Raj PrasadRPRaj Prasad
- Giles ToogoodGTGiles Toogood
- Christy RalphCRChristy Ralph
- D. Alan AnthoneyDAD. Alan Anthoney
- Alan A. MelcherAMAlan A. Melcher
Open Access
Abstract
Pexa-Vec is an engineered Wyeth-strain vaccinia oncolytic virus (OV), which has been tested extensively in clinical trials, demonstrating enhanced cytotoxic T cell infiltration into tumours following treatment. Favourable immune consequences to Pexa-Vec include the induction of an interferon (IFN) response, followed by inflammatory cytokine/chemokine secretion. This promotes tumour immune infiltration, innate and adaptive immune cell activation and T cell priming, culminating in targeted tumour cell killing, i.e., an immunologically ‘cold’ tumour microenvironment is transformed into a ‘hot’ tumour. However, as with all immunotherapies, not all patients respond in a uniformly favourable manner. Our study herein, shows a differential immune response by patients to intravenous Pexa-Vec therapy, whereby some patients responded to the virus in a typical and expected manner, demonstrating a significant IFN induction and subsequent peripheral immune activation. However, other patients experienced a markedly subdued immune response and appeared to exhibit an exhausted phenotype at baseline, characterised by higher baseline immune checkpoint expression and regulatory T cell (Treg) levels. This differential baseline immunological profile accurately predicted the subsequent response to Pexa-Vec and may, therefore, enable the development of predictive biomarkers for Pexa-Vec and OV therapies more widely. If confirmed in larger clinical trials, these immunological biomarkers may enable a personalised approach, whereby patients with an exhausted baseline immune profile are treated with immune checkpoint blockade, with the aim of reversing immune exhaustion, prior to or alongside OV therapy.Keywords
Funding Information
- Transgene (Strasbourg)
- Yorkshire Cancer Research, Cancer Research UK
- Institute of Cancer Research/Royal Marsden NIHR Biomedical Research Centre
This publication has 75 references indexed in Scilit:
- Th9 cells promote antitumor immune responses in vivoJournal of Clinical Investigation, 2012
- Regulation of innate CD8+T-cell activation mediated by cytokinesProceedings of the National Academy of Sciences, 2012
- Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in PatientsCancer Research, 2012
- Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination EfficacyMolecular Therapy, 2011
- Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingMolecular Cancer, 2011
- IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune SuppressionThe Journal of Immunology, 2011
- Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor ImmunityClinical Cancer Research, 2008
- M-CSF: a novel plasmacytoid and conventional dendritic cell poietinBlood, 2008
- Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sitesJournal of Clinical Investigation, 2007
- Cytotoxic T lymphocyte antigen‐4‐dependent down‐modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T‐cell‐mediated suppressionImmunology, 2006